Neoplasma. 2017;64(5):803-808. doi: 10.4149/neo_2017_520.
Salvage therapy for recurrent high grade gliomas (HGG) includes surgery, radiotherapy and chemotherapy, however, standard treatment does not exist. We evaluated the tolerability and efficacy of re-irradiation (re-RT) with hyperthermia (HT) for patients with recurrent HGG. From September 2010 to July 2015, 20 patients with recurrent HGG were treated with re-RT and HT. The radiotherapy dose of 30 Gray (Gy) was delivered with 2 Gy per fraction daily, and HT was performed twice weekly. Primary endpoints were treatment compliance and toxicity. Second endpoints were overall survival (OS) and progression free survival (PFS). The median interval between initial RT and re-RT was 11 months. During re-RT with HT, there were no significant acute morbidities over grade 3. Median overall survival (OS) from re-irradiation was 8.4 months and the 6 and 12 months survival rate were 67% and 30%, respectively. The median progression free survival (PFS) from re-irradiation was 4.1 month. Our findings suggested that concurrent re-RT with HT was a safe and well-tolerated. In addition, the combination re-RT and HT could be a valuable salvage treatment option for selected recurrent HGG patients with poor performance status.
复发性高级别胶质瘤（HGG）的挽救性治疗包括手术、放疗和化疗，但尚无标准治疗方法。我们评估了复发性 HGG 患者接受再放疗（re-RT）联合热疗（HT）的耐受性和疗效。自 2010 年 9 月至 2015 年 7 月，20 例复发性 HGG 患者接受了 re-RT 和 HT 治疗。放疗剂量为 30 戈瑞（Gy），每日 2 Gy 分 2 次给予，HT 每周进行 2 次。主要终点是治疗依从性和毒性。次要终点是总生存期（OS）和无进展生存期（PFS）。初始 RT 与 re-RT 之间的中位间隔为 11 个月。在 re-RT 联合 HT 期间，无 3 级以上急性并发症。从 re-irradiation 开始的中位总生存期（OS）为 8.4 个月，6 个月和 12 个月的生存率分别为 67%和 30%。从 re-irradiation 开始的中位无进展生存期（PFS）为 4.1 个月。我们的研究结果表明，同期 re-RT 联合 HT 是一种安全且耐受性良好的治疗方法。此外，对于合并有较差体能状态的复发性 HGG 患者，re-RT 联合 HT 可能是一种有价值的挽救性治疗选择。
